Ardelyx reports fewer gastrointestinal visits after IBSRELA treatment
Ardelyx presented real-world findings at the ACG 2026 Annual Scientific Meeting on October 12, 2026, covering 470 adults with IBS-C who began IBSRELA (tenapanor). Median gastrointestinal-related healthcare visits fell from 4.5 in the preceding year to 3.0 in the subsequent year, with P<0.001. Ardelyx also presented IBS-C quality-of-life research and the design of an ongoing Phase 3 study of tenapanor in adults with chronic idiopathic constipation.
Why it matters
The findings provide additional utilization data for Ardelyx's marketed IBS-C therapy, but the retrospective design does not establish that treatment caused the decline. The ongoing Phase 3 study could provide further evidence for tenapanor in chronic idiopathic constipation, although no results were reported.
Key facts
- 1The retrospective analysis covered 470 patients with IBS-C treated at a national gastroenterology practice. stocktitan.net
- 2Median gastrointestinal-related healthcare utilization declined from 4.5 visits in the year before tenapanor began to 3.0 visits in the following year, with P<0.001. stocktitan.net
- 3Ardelyx scheduled a poster on the design and rationale of a Phase 3, 26-week randomized controlled tenapanor study for chronic idiopathic constipation. stocktitan.net
- 4The ACG 2026 presentations also included an analysis linking IBS-C symptom severity with quality of life. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.